Géraldine Honnet
Chief Tech/Sci/R&D Officer at SENSORION
Profile
Géraldine Honnet is currently the Chief Medical Officer at Sensorion SA since 2020.
Prior to this, she worked as the Director-Development at Genethon from 2017 to 2020, as a Senior Clinical Manager at Transgene SA from 2007 to 2011, and as a Medical Director at PAREXEL International Corp.
from 2001 to 2005.
Géraldine Honnet active positions
Companies | Position | Start |
---|---|---|
SENSORION | Chief Tech/Sci/R&D Officer | 2020-02-17 |
Former positions of Géraldine Honnet
Companies | Position | End |
---|---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Corporate Officer/Principal | 2019-12-31 |
TRANSGENE | Corporate Officer/Principal | 2011-03-31 |
PAREXEL INTERNATIONAL CORPORATION | Chief Tech/Sci/R&D Officer | 2005-08-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
TRANSGENE | Health Technology |
SENSORION | Health Technology |
Private companies | 2 |
---|---|
PAREXEL International Corp.
PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
- Stock Market
- Insiders
- Géraldine Honnet